Dr. Jason Westin on Combination Targeted Therapy Prior to Chemotherapy for DLBCL

June 11, 2019
Jason Westin, MD

Cancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL.

Cancer Network spoke with Jason Westin, MD, of MD Anderson Cancer Center, about the Smart Start trial, which showed that a combination of targeted therapy prior to chemotherapy proved to be effective in patients with DLBCL.

Related Content:

American Society of Clinical Oncology Annual Meeting (ASCO)LeukemiaDiffuse Large B-Cell LymphomaLymphoma
Real-World Data Suggest Systemic High-Dose and Intrathecal MTX Lower CNS Relapse Incidence for DLBCL
Matthew J. Matasar, MD, on the Clinical Implications of the Phase 3 CHRONOS-3 Study
Matthew J. Matasar, MD, Discusses ‘Breadth of Scientific Investigation’ at AACR Annual Meeting